

# **Nobiletin Datasheet**

4<sup>th</sup> Edition (Revised in July, 2016)

# [ Product Information ]

Name: Nobiletin

Catalog No.: CFN98726

Cas No.: 478-01-3

**Purity: >=98%** 

M.F: C<sub>21</sub>H<sub>22</sub>O<sub>8</sub>

M.W: 402.39

Physical Description: Powder

**Synonyms:** 1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane;1,8-Cineole;Eucalyptol;

1,8-Epoxy-p-menthane;1,8-Oxido-p-menthane.

## [ Intended Use ]

- 1. Reference standards;
- 2. Pharmacological research;
- 3. Synthetic precursor compounds;
- 4. Intermediates & Fine Chemicals;
- 5. Others.

### [Source]

The peel of Citrus nobilis Lour.

# [ Biological Activity or Inhibitors]

Nobiletin, a citrus polymethoxy flavonoid, has anti-inflammatory actions on human synovial

fibroblasts and mouse macrophages.[1]

Nobiletin has inhibitory effect on phorbol ester-induced skin inflammation, oxidative stress,

and tumor promotion mice, it is a functionally novel and possible chemopreventive agent

in inflammation-associated tumorigenesis.[2]

Nobiletin decreases the Abeta burden and plaques in the hippocampus of APP-SL 7-5 Tg

mice, it improves memory impairment and Abeta pathology in a transgenic mouse model

of Alzheimer's disease. [3]

Nobiletin has anti-tumour effects and antiproliferative effects via induction of apoptosis

and cell cycle deregulation.[4]

Nobiletin exhibits various pharmacological effects including anti-inflammatory, antitumor

and neuroprotective properties, it improves hyperglycemia and insulin resistance in obese

diabetic ob/ob mice.[5]

Nobiletin improves brain ischemia-induced learning and memory deficits through

stimulation of CaMKII and CREB phosphorylation. [6]

[Solvent]

Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

[ HPLC Method ]<sup>[7]</sup>

Mobile phase: Acetonitrile - H2O=45:55;

Flow rate: 1.0 ml/min;

Column temperature: 25  $^{\circ}$ C;

The wave length of determination: 333 nm.

[Storage]

2-8℃, Protected from air and light, refrigerate or freeze.

#### [References]

- [1] Lin N, Sato T, Takayama Y, et al. Biochem. Pharmacol., 2003, 65(12):2065-71.
- [2] Murakami A, Nakamura Y, Torikai K,et al .Cancer Res., 2000, 60(18):5059-66.
- [3]Onozuka H, Nakajima A, Matsuzaki K, et al. J.Pharmacol. Exp. Ther., 2008, 326(3):739-44.
- [4] Yoshimizu N, Otani Y, Saikawa Y, et al. Aliment. Pharm. Therap., 2004, 20 Suppl 1(Supplement s1):95-101.
- [5] Lee Y S, Cha B K, Yamakawa H, et al. Biochem. Pharmacol., 2010, 79(11):1674-83.
- [6] Yamamoto Y, Shioda N, Feng H, et al. Brain Res. 2009, 1295:218-29.
- [7] Luo X, Weifeng L I, Niu X, et al. Northwest Pharmaceutical Journal, 2014(2):140-2.

#### [ Contact ]

#### Address:

S5-3 Building, No. 111, Dongfeng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056,

China

Email: info@chemfaces.com

Tel: +86-27-84237783

Fax: +86-27-84254680

Web: www.chemfaces.com

Tech Support: service@chemfaces.com